ABIOMED Inc (ABMD)

NASDAQ
381.02
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    380.51 - 381.28
  • 52 wk Range:
    219.85 - 381.99

ABMD Overview

Prev. Close
381.02
Day's Range
380.51-381.28
Revenue
1.05B
Open
380.78
52 wk Range
219.85-381.99
EPS
5.86
Volume
0
Market Cap
17.19B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,566,750
P/E Ratio
65.38
Beta
1.4
1-Year Change
23.72%
Shares Outstanding
45,110,225
Next Earnings Date
Feb 02, 2023
What is your sentiment on ABIOMED?
or
Market is currently closed. Voting is open during market hours.

ABIOMED Inc News

ABIOMED Inc Analysis

ABIOMED Inc Company Profile

ABIOMED Inc Company Profile

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro-heart pump with an integrated motor and sensors, and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro-heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; the Impella SmartAssist platform, which includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staff; and the OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in Germany, France, the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts with additional offices in Halethorpe, Maryaland, Aachen, and Berlin, Germany, and Tokyo, Japan. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • This stock is really savage. Best medical company and in a specialized field in their field they are best. Super professional.This company will cross $200 in next year which is almost 20% gain on Abmd.Best price to hop on. it might not be bought on thic price ever again.Rally stock, will hit the sky. BULLISH👍.
    0